TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05994508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pickleball program
Description: The intervention will be a 6-week pickleball program, at a frequency of two times a week. Each session will be one hour which will consist of dynamic warm-up drills, pickleball-related skill practice and game play, and a cool-down period.
Study: NCT06284850

Intervention type: DRUG
Intervention: Empagliflozin10Mg Tab
Description: TB JARDIANCE 10MG
Study: NCT05133154

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: In total, about 20 ml of blood will be collected on EDTA tubes : collection of CTCs, TEPs and biobanking (V0, V1 and V2)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: In total, about 20 ml of blood will be collected on EDTA tubes : collection of CTCs, TEPs and biobanking (V0, V1 and V2)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: In total, about 20 ml of blood will be collected on EDTA tubes : collection of CTCs, TEPs and biobanking (V0, V1 and V2)
Study: NCT06415513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASMR
Description: We used 7 ASMR videos published on the most watched ASMR channel on the YouTube platform, in which applications such as hair combing, brushing, massaging the head are applied sequentially and repeatedly, and there is no speech.
Study: NCT04963452

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dural puncture epidural
Description: Parturients, between 18 and 45 years of age, with cervical dilation less than 5 cm were consented to receive a DPE technique, with a single dural puncture with a 26-gauge spinal needle. After successful placement of the epidural catheter and puncturing the dura; 20 mL of bupivacaine 0.25% was administered through the epidural catheter and a patient-controlled epidural infusion of bupivacaine was initiated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dural puncture epidural
Description: Parturients, between 18 and 45 years of age, with cervical dilation less than 5 cm were consented to receive a DPE technique, with a single dural puncture with a 26-gauge spinal needle. After successful placement of the epidural catheter and puncturing the dura; 20 mL of bupivacaine 0.25% was administered through the epidural catheter and a patient-controlled epidural infusion of bupivacaine was initiated.
Study: NCT05598736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowOx 2.0
Description: -40mmHg intermittent negative pressure for 60 minutes per day
Study: NCT04865809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peribioma Toothpaste and Mousse
Description: Use of Peribioma Toothpaste and Mousse for home oral care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard toothpaste
Description: Use of Biorepair Plus Parodontgel for home oral care
Study: NCT05229913

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esketamine is not added
Description: Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.2mg/kg
Description: Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.4mg/kg
Description: Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.6mg/kg
Description: Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.8mg/kg
Description: Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
Study: NCT03848663

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Remapping
Description: Shifting text outside of scotoma

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Remapping
Description: Shifting text outside of scotoma

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Remapping
Description: Shifting text based on individual letter-based perimetry

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Remapping
Description: Shifting text based on individual letter-based perimetry
Study: NCT06237179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training Intervention
Description: 5.1. The behavioral ET and HLE interventions will be delivered over 12 weeks. Before starting the study, men will be asked to attend one (1) in-person small group orientation to provide an overview of each intervention arm, familiarize them with web-based and smartphone applications or hard copy manuals for delivery of intervention content, exercise logs, resistance bands, and equipment for strength training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Education
Description: During the initial 12 weeks of the study, men randomized to the HLE group will receive educational modules delivered remotely (or manual and telephone call) in a group-based setting to approximately match contact frequency and structure with the ET arm.
Study: NCT05964062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS treatment
Description: Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS treatment
Description: The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
Study: NCT05096715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous Infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Description: External Beam Radiation
Study: NCT05055765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: MN will be carried out 1mm below of the gingival margin on the gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injectable- platelet rich fibrin
Description: I-PRF will be prepared according to Choukroun PRF method.
Study: NCT01637168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin
Description: A tablet, 2 times daily (12/12 hours).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba (Tebonin®)
Description: A tablet, 2 times daily (12/12 hours).
Study: NCT05331092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: 20 minutes of cryotherapy on the dominant ankle with ice bags
Study: NCT06072040

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AUR-201
Description: Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
Study: NCT04771754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 50 mg once daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 50 mg once daily orally
Study: NCT05747300

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Premixed bioceramic paste wellroot PT
Description: Vital pulpotomy primary Molars using premixed bioceramic paste wellrootPT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Premixed bioceramic paste wellroot PT
Description: Vital pulpotomy primary Molars using premixed bioceramic paste wellrootPT
Study: NCT06253182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Guided PEPP Intervention Workbook
Description: The workbook contains 3 modules. To complete the workbook in six weeks (one module every 2 weeks), it is recommended that a dyad schedule at least three 30-minute blocks of time each week. Dyads are asked to work through the modules in order and encouraged to set a pace that works for them.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided PEPP Education Workbook
Description: The workbook contains 3 modules. To complete the workbook in six weeks (one module every 2 weeks), it is recommended that a dyad schedule at least three 30-minute blocks of time each week. Dyads are asked to work through the modules in order and encouraged to set a pace that works for them.
Study: NCT06533826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: A HER2-directed ADC, 100mg/vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: A HER2-directed ADC, 100mg/vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: A HER2-directed ADC, 100mg/vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: A HER2-directed ADC, 100mg/vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: A TROP2-directed antibody drug conjugate, 100mg/vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: A TROP2-directed antibody drug conjugate, 100mg/vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: A TROP2-directed antibody drug conjugate, 100mg/vial, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: A TROP2-directed antibody drug conjugate, 100mg/vial, via intravenous (into the vein) infusion per protocol.
Study: NCT04819659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pharyngeal packing
Description: Placing gauze-like material in the nasal cavity to absorb blood or other fluids right after tracheal intubation.
Study: NCT05531162

Intervention type: OTHER
Group type: OTHER
Intervention: Cognition and emotional neuropsychologicl evaluations
Description: Cognitive ans sensory performances during repetitive micro and partial gravity exposure
Study: NCT05201391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat Right Now (ERN) mobile application
Description: Eat Right Now (ERN) is an app-based (28 daily modules, self-paced) Mindfulness-Based Intervention (MBI), which uses mindfulness to target craving-based eating. The program is designed to take 6-8 weeks to complete.
Study: NCT05299268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain (hypertonic saline)
Description: A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No pain (Isotonic saline)
Description: A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension
Study: NCT00449124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of 0.5 mL of normal saline solution (0.9% NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of 0.5 mL of normal saline solution (0.9% NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of 0.5 mL of normal saline solution (0.9% NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of 0.5 mL of normal saline solution (0.9% NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of 0.5 mL of normal saline solution (0.9% NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of 0.5 mL of normal saline solution (0.9% NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of 0.5 mL of normal saline solution (0.9% NaCl).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4040
Description: Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10\^6 PFU, TG4040 10\^7 PFU and TG4040 10\^8 PFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4040
Description: Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10\^6 PFU, TG4040 10\^7 PFU and TG4040 10\^8 PFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4040
Description: Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10\^6 PFU, TG4040 10\^7 PFU and TG4040 10\^8 PFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4040
Description: Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10\^6 PFU, TG4040 10\^7 PFU and TG4040 10\^8 PFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4040
Description: Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10\^6 PFU, TG4040 10\^7 PFU and TG4040 10\^8 PFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4040
Description: Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10\^6 PFU, TG4040 10\^7 PFU and TG4040 10\^8 PFU.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4040
Description: Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10\^6 PFU, TG4040 10\^7 PFU and TG4040 10\^8 PFU.
Study: NCT06085599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises
Description: The progressive muscle relaxation technique involves suggestive stretching and relaxation in sixteen different muscle groups of the body. This technique is based on tensing each muscle group for approximately 10 seconds and then abruptly releasing this tension.
Study: NCT05471544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine
Description: Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Description: Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect.
Study: NCT05072106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin
Description: 3.2 mg/m² as a 1-hour i.v. infusion on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin
Description: 3.2 mg/m² as a 1-hour i.v. infusion on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: Bosentan: 125 mg (one film-coated tablet of 125 mg) orally (p.o.) twice daily in the morning and in the evening during the prior five consecutive days before the day of lurbinectedin infusion (Day 1), and once daily on Day 1 (before lurbinectedin infusion).
Study: NCT04618289

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3-fortified fruit juice supplement
Description: Vitamin D3-fortified fruit juice supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified fruit juice supplement
Description: Vitamin D3-fortified fruit juice supplement
Study: NCT04803851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib plus AK105
Description: Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody
Study: NCT06097026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Description: Progressive pressure increase on the ventilator to recruit collapsed alveoli and improve pulmonary ventilation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Administer nitric oxide upon arrival from cardiac surgery and assess cardiac and pulmonary function afterwards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Administer nitric oxide upon arrival from cardiac surgery and assess cardiac and pulmonary function afterwards.
Study: NCT05268445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemical and Mechanical Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis
Description: Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemical and Mechanical Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis
Description: Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis
Study: NCT05253300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positioning the patient
Description: The patients' vital signs, pain and analgesic drug use were recorded in the Pain Follow-up Form at the time they came to the clinic, at the 6th and 12th hours after the surgery, by recording from the end-of-operation file. In case the patient had pain, the time when the pain started was recorded, the experimental group was given the semi-recumbent position with analgesic drug and the patient was asked to maintain this position for 2 hours. If the patient has pain again, this position is given again. Patient Satisfaction Evaluation Form was filled in at the 12th hour after the surgery for the patients in the experimental group.
Study: NCT06424132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Vest Exposure Period
Description: A cold vest will be placed on the participant which consists of a water-perfused wearable vest, size S-M or M-L with adjustable straps attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler (Polar Products, Stow, OH- Product link: www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm) This product is safe and recommended by experimental guidelines for human BAT studies. Participants will be cold exposed for a period of 3 hours resting in a reclined position engaged in reading and/or digital entertainment of their choice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Vest Exposure Period
Description: A cold vest will be placed on the participant which consists of a water-perfused wearable vest, size S-M or M-L with adjustable straps attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler (Polar Products, Stow, OH- Product link: www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm) This product is safe and recommended by experimental guidelines for human BAT studies. Participants will be cold exposed for a period of 3 hours resting in a reclined position engaged in reading and/or digital entertainment of their choice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Vest Exposure Period
Description: A cold vest will be placed on the participant which consists of a water-perfused wearable vest, size S-M or M-L with adjustable straps attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler (Polar Products, Stow, OH- Product link: www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm) This product is safe and recommended by experimental guidelines for human BAT studies. Participants will be cold exposed for a period of 3 hours resting in a reclined position engaged in reading and/or digital entertainment of their choice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rewarming Exposure Period
Description: Following cold exposure, the cold vests will be removed, and participants will be offered a warm blanket to ease the transition from cold back to warm temperatures. Participants will then be moved to an adjacent warm room maintained at 30 degrees celsius and asked to return to the resting position of their choice. Participants will then engage in reading and/or digital entertainment for a 3-hour warm exposure period.
Study: NCT06273150

Intervention type: OTHER
Intervention: Positive genetic test for pathological expansion in ATN1
Description: Positive genetic test for pathological expansion in ATN1

Intervention type: OTHER
Intervention: Positive genetic test for pathological expansion in ATN1
Description: Positive genetic test for pathological expansion in ATN1
Study: NCT05532358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anle138b (TEV-56286)
Description: Anle138b (TEV-56286) as perpetrator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg QD for 5 days
Description: Anle138b (TEV-56286) as victim